Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL7871661 | 0.98 | HPGD (0.54) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL17229380 | 0.94 | HPGD (0.57) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL12136991 | 0.90 | NR1H2 (0.50) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL8426435 | 0.90 | NR1H2 (0.50) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL14514518 | 0.90 | NR1H2 (0.50) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL23135748 | 0.89 | GPR119 (0.50) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL415679 | 0.88 | HPGD (0.59) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL792459 | 0.88 | HPGD (0.54) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL26351282 | 0.88 | GPR119 (0.53) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL15085735 | 0.87 | HPGD (0.57) | HPGDKDM4EPKMRECQLEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 335 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | US | disclosed |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3782996-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-04-10 | — | — | EP | disclosed |
| EP-3555078-B1 | BISARYL HETEROCYCLES AS NRF2 ACTIVATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-03-27 | — | — | EP | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| WO-2023191951-A1 | SMALL MOLECULE ALLOSTERIC MODULATORS OF THE SEROTONIN (5-HT) 5-HT2C AND 5-HT2A RECEPTORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| US-11771738-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-20070142377-A1 | Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives | BIEDERMANN ELFI | 2007-06-21 | — | — | US | disclosed |
| US-20070117847-A1 | N-(3-(4-Substituted-1-piperiding1)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | CHAMBERS MARK S | 2007-05-24 | — | — | US | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-20070021439-A1 | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2004024060-A2 | METALLOPROTEINASE INHIBITORS AND INTERMEDIATES FOR PREPARATION THEREOF | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004020415-A1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | WO | disclosed |
| US-20040002504-A1 | N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | MERCK SHARP & DOHME LTD. (GB) | 2004-01-01 | — | — | US | disclosed |
| EP-0617968-B1 | HIV protease inhibitors in pharmaceutical combinations for the treatment of AIDS | MERCK & CO INC (US) | 2003-01-08 | — | — | EP | disclosed |
| CN-1290251-A | N-acyl cyclic amine derivatives | BANYU PHARMA CO LTD (JP) | 2001-04-04 | — | — | CN | disclosed |
| CN-1237170-A | Novel tricyclic piperidinyl compounds useful as inhibitors of farnesyl protein transferase | SCHERING CORP (US) | 1999-12-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002504-A1 | N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | KCNH3, KCNH2, KCNK3 | HPGD 4067/4885KDM4E 1083/4885PKM 2028/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | HPGD 283/4885KDM4E 2846/4885PKM 564/4885 |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | HPGD 1357/4885KDM4E 1333/4885PKM 1731/4885 |
| US-20070142377-A1 | Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives | ALK, TYMP, PDCD1 | HPGD 580/4885KDM4E 2336/4885PKM 1045/4885 |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | HPGD 2067/4885KDM4E 473/4885PKM 3906/4885 |
| US-11771738-B2 | Endoparasitic depsipeptides | VIP, PREP, VIPR1 | HPGD 1639/4885KDM4E 4092/4885PKM 2509/4885 |
| US-20070117847-A1 | N-(3-(4-Substituted-1-piperiding1)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | TACR2, KCNK3, KCNH3 | HPGD 3272/4885KDM4E 992/4885PKM 1683/4885 |
| US-20070021439-A1 | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers | KCNN2, KCNN1, KCNN3 | HPGD 778/4885KDM4E 4305/4885PKM 2487/4885 |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ADORA2A, ADORA1, ADORA2B | HPGD 2234/4885KDM4E 4126/4885PKM 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.